Article info
PDFResearch ethics
Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis
- Correspondence to: J Kimmelman Clinical Trials Research Group, Biomedical Ethics Unit, Faculty of Medicine/McGill University, 3647 Peel Street, Montreal, Quebec H3A 1X1, Canada; jonathan.kimmelmanmcgill.ca
Citation
Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis
Publication history
- Received August 13, 2003
- Accepted February 5, 2004
- Revised January 8, 2004
- First published March 30, 2005.
Online issue publication
April 27, 2016
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2005 by the Journal of Medical Ethics
Other content recommended for you
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
- Therapeutic appropriation: a new concept in the ethics of clinical research
- Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study)
- Two concepts of therapeutic optimism
- Phase I oncology trials: why the therapeutic misconception will not go away
- Abortion decisions as inclusion and exclusion criteria in research involving pregnant women and fetuses
- Phase 1 oncology trials and informed consent
- Are positive experiences of children in non-therapeutic research justifiable research benefits?
- Beyond informed consent: the therapeutic misconception and trust
- Sham neurosurgery in patients with Parkinson's disease: is it morally acceptable?